# SAFETY DATA SHEET



# 1. Identification

**Product identifier Etesevimab Injection** 

Other means of identification

**Item Code** 702912, 702950, 702920, CT7834, 702783, 702881, VL7950, CT9758, 702770 LY-CoV016 \* 3832479 Injection \* JS016 \* LA856 \* LY3832479 drug product **Synonyms** 

LY3832479 LY Number Recommended use Pharmaceutical **Recommended restrictions** None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company **Address** Lilly Corporate Center Indianapolis, IN 46285

**United States** 

Phone: Telephone +1-317-276-2000

E-mail lilly\_sds@lilly.com

CHEMTREC: **Emergency phone number** +1-800-424-9300

2. Hazard(s) identification

**Physical hazards** Not classified. **Health hazards** Not classified. Not classified. **OSHA** defined hazards

Label elements

None. **Hazard symbol** Signal word None.

The mixture does not meet the criteria for classification. **Hazard statement** 

**Precautionary statement** 

Prevention Not available. Response Not available. Storage Not available. **Disposal** Not available. Hazard(s) not otherwise None known.

classified (HNOC)

**Supplemental information** None.

### 3. Composition/information on ingredients

### **Mixtures**

Chemical name	Common name and synonyms	CAS number	%
Etesevimab		2423948-94-9	< 5

**Composition comments** Remaining components of this product are non-hazardous and/or are present at concentrations

below reportable levels.

4. First-aid measures

Inhalation Call a physician if symptoms develop or persist.

Rinse skin with water/shower. Get medical attention if irritation develops and persists. Skin contact

Rinse with water. Get medical attention if irritation develops and persists. Eye contact

Ingestion Get medical attention if symptoms occur.

Material name: Etesevimab Injection SDS US 1/5 Most important

symptoms/effects, acute and

delayed

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to produce health effects through relevant routes of occupational exposures.

Indication of immediate medical attention and special treatment needed

None known.

# 5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Specific hazards arising from

the chemical Special protective equipment Not applicable.

Not available.

and precautions for firefighters

Wear suitable protective equipment.

General fire hazards This product is an aqueous mixture which will not burn.

### 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Avoid inhalation of mists or aerosols.

Methods and materials for containment and cleaning up Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum.

Wear appropriate protective equipment and clothing during clean-up.

Use fire-extinguishing media appropriate for surrounding materials.

**Environmental precautions** Avoid release to the environment.

# 7. Handling and storage

Precautions for safe handling

Conditions for safe storage, including any incompatibilities Not available.

Keep container tightly closed in a dry and well-ventilated place.

# 8. Exposure controls/personal protection

Occupational exposure limits

1 :Us. /I EQ

Components	Туре	Value	
Etesevimab (CAS 2423948-94-9)	TWA (12hrs)	250 μg/m3	
	TWA (8hrs)	380 μg/m3	

No biological exposure limits noted for the ingredient(s). **Biological limit values Exposure guidelines** Health Based Excursion Limit: Maintain Full Shift TWA

Appropriate engineering

controls

Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational

exposure level (OEL).

### Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear

impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an Respiratory protection

approved respirator with sufficient protection factor to control exposure below the OEL.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

Material name: Etesevimab Injection 7497 Version #: 06 Revision date: 06-22-2021 Issue date: 10-13-2020

### 9. Physical and chemical properties

**Appearance** 

Liquid. **Physical state** 

**Aqueous Solution Form** 

Color Colorless. Odor Odorless **Odor threshold** Not available.

pН

Melting point/freezing point Not available. Not available. Initial boiling point and boiling

range

Flash point Not available. **Evaporation rate** Not available. Flammability (solid, gas) Not applicable. Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

Not available.

Not available.

(%)

Not available. Explosive limit - lower (%) Explosive limit - upper (%) Not available. Not available. Vapor pressure Vapor density Not available.

Relative density Solubility(ies)

> Soluble Solubility (water)

**Partition coefficient** Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. **Viscosity** 

Other information

**Explosive properties** Not explosive.

**Oxidizing properties** No oxidizing properties.

10. Stability and reactivity

Not water reactive. Reactivity

Material is stable under normal conditions. **Chemical stability** Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoid None under normal conditions.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

# 11. Toxicological information

Information on toxicological effects

Based on available data, the classification criteria are not met. Acute toxicity Based on available data, the classification criteria are not met. Skin corrosion/irritation Based on available data, the classification criteria are not met. Serious eye damage/eye

irritation

Material name: Etesevimab Injection

7497 Version #: 06 Revision date: 06-22-2021 Issue date: 10-13-2020

Respiratory or skin sensitization

Respiratory sensitization Due to inconclusive data the classification criteria are not met. Due to inconclusive data the classification criteria are not met. Skin sensitization

Germ cell mutagenicity This substance is a monoclonal antibody. It does not possess mutagenic potential.

Mutagenicity testing has not been conducted.

Carcinogenicity Not listed by IARC, NTP, ACGIH or OSHA.

Due to inconclusive data the classification criteria are not met.

#### IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

# OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

#### US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity Based on available data, the classification criteria are not met.

Specific target organ toxicity single exposure

No significant target organ toxicity reported. (intravenous) (Etesevimab)

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

repeated exposure

No significant target organ toxicity reported. (intravenous) (Etesevimab)

Based on available data, the classification criteria are not met.

**Aspiration hazard** Based on available data, the classification criteria are not met.

**Further information** This substance is a monoclonal antibody. Based on the biophysical properties and absorption

characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered

occupationally relevant and potential bioavailability through inhalation is minimal.

# 12. Ecological information

**Ecotoxicity** Not expected to be harmful to aquatic organisms.

Persistence and degradability Not available. Not available. Bioaccumulative potential Not available. Mobility in soil Not available. Other adverse effects

### 13. Disposal considerations

Dispose in accordance with all applicable regulations. **Disposal instructions** 

#### 14. Transport information

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

**IMDG** 

Not regulated as dangerous goods.

Transport in bulk according to

Not available.

Annex II of MARPOL 73/78 and

the IBC Code

### 15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

**Toxic Substances Control Act (TSCA)** 

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

**CERCLA Hazardous Substance List (40 CFR 302.4)** 

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Material name: Etesevimab Injection SDS US

### Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

### Other federal regulations

#### Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

### Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

#### **International Inventories**

Country(s) or region On inventory (yes/no)\* Inventory name Canada Domestic Substances List (DSL) Canada Non-Domestic Substances List (NDSL) No

Toxic Substances Control Act (TSCA) Inventory United States & Puerto Rico No

# 16. Other information, including date of preparation or last revision

10-13-2020 Issue date **Revision date** 06-22-2021

Version # 06

ACGIH: American Conference of Governmental Industrial Hygienists. List of abbreviations

> DOT: Department of Transportation (49 CFR 172.101). IARC: International Agency for Research on Cancer. IATA: International Air Transport Association.

IMDG Code: International Maritime Dangerous Goods Code. NIOSH: National Institute for Occupational Safety & Health. OSHA: Occupational Safety & Health Administration.

PEL: Permissible Exposure Limit. TLV: Threshold Limit Value.

As of the date of issuance, we are providing available information relevant to the handling of this Disclaimer

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company **Hazard Communication** +1-317-651-9533

**Revision information** Product and Company Identification: Synonyms

Exposure controls/personal protection: Exposure guidelines

Material name: Etesevimab Injection SDS US

<sup>\*</sup>A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).